LivaNova wins FDA approval for aura6000 sleep apnea implant

LivaNova’s aura6000 system has won U.S. FDA premarket approval for treating adults with moderate to severe obstructive sleep apnea, giving the company a long-awaited entry into the implantable sleep apnea device market. FDA’s PMA database lists the decision date as March 18, 2026, and says the device is indicated for adults with an apnea-hypopnea index of 15 to 65 who have failed, don’t tolerate, or aren’t eligible for standard-of-care options such as PAP, oral appliances, or pharmacotherapy. (accessdata.fda.gov)

The approval follows several years of clinical and regulatory work. LivaNova said in 2021 that FDA had cleared its investigational device exemption study for aura6000, launching the OSPREY trial after earlier work with the THN-3 study and after the device had already received a CE mark in Europe. In May 2025, the company disclosed that it had completed its PMA submission, setting up the 2026 FDA decision. (investor.livanova.com)

At the center of the filing was OSPREY, a prospective, multicenter, randomized, controlled, open-label trial comparing active therapy with no stimulation in people with moderate to severe OSA who had failed or were unwilling to use PAP. LivaNova reported in late 2024 that OSPREY met its primary safety and efficacy endpoints, and later said the treatment arm posted a 65% responder rate at 12 months. In the trial, a responder was defined as achieving at least a 50% improvement from baseline AHI and an AHI below 20. (investor.livanova.com)

What appears to distinguish aura6000 is its proximal hypoglossal nerve stimulation approach. LivaNova has said the system uses six electrodes placed on the proximal trunk of the hypoglossal nerve, aiming to provide broader access to airway-controlling muscles and allow customized titration. Industry coverage following the FDA decision also highlighted a potentially important commercial point: aura6000 appears to be the first FDA-approved hypoglossal nerve stimulation therapy in the U.S. without a listed contraindication or warning tied to complete concentric collapse, a feature that could reduce pre-implant workup complexity for some patients and clinicians. That said, the strongest support for that distinction comes from company-linked and trade reporting; clinicians will still want to scrutinize the final labeling and real-world payer requirements closely. (accessdata.fda.gov)

The competitive backdrop matters. Inspire remains the established FDA-approved upper airway stimulation device in OSA, and its current FDA-cleared labeling includes a restriction for patients who have complete concentric collapse of the soft palate. Inspire’s indication was expanded in 2023 to include patients with AHI up to 100 and BMI up to 40, underscoring how mature and entrenched that platform already is. LivaNova is entering a market with a known clinical need, but also with an incumbent that already has physician familiarity, registry data, and commercial infrastructure. (fda.gov)

The aura6000 approval also lands in a broader neuromodulation moment. Separate from sleep apnea, FDA has recently shown support for other implantable neurostimulation platforms, including Nia Therapeutics’ Smart Neurostimulation System, which received Breakthrough Device designation for episodic memory loss in adults with prior moderate to severe traumatic brain injury and persistent deficits. Nia describes that system as a fully implantable, closed-loop platform that records neural activity from 60 channels across four brain regions and delivers targeted stimulation to the lateral temporal cortex. In a sham-controlled study in neurosurgical patients with epilepsy and a history of TBI, the company said the device improved recall by 19%, while random stimulation showed no benefit; it plans to file an IDE application in 2026. That is a very different indication and a much earlier regulatory stage than aura6000’s PMA approval, but it reinforces the larger point that implantable neurotechnology is expanding into chronic, function-limiting disorders beyond movement disorders and pain.

Why it matters: For veterinary professionals, this isn’t a companion animal regulatory event, but it is still relevant as a signal about where implantable neurostimulation is heading. Human medtech approvals often shape investor attention, platform development, reimbursement conversations, and translational thinking that can eventually influence adjacent fields, including specialty veterinary care. More immediately, it’s a reminder that chronic disease management is moving beyond drugs and external devices toward implanted systems that promise better adherence in patients who don’t stay on first-line therapy. In OSA specifically, that adherence problem is central, since aura6000 is indicated only after standard options have failed, been poorly tolerated, or judged unsuitable. The parallel activity in memory-focused closed-loop stimulation also suggests the field is broadening not just commercially, but technically, toward more targeted and responsive implanted systems. (accessdata.fda.gov)

Expert voices around the program have emphasized the unmet need. In LivaNova’s scientific communications, Chief Innovation Officer Ahmet Tezel said nearly 2 million patients with moderate to severe OSA have failed first-line therapies, while OSPREY lead investigator Atul Malhotra and other sleep specialists were featured in company-sponsored scientific programming around the trial’s results. Those comments should be read with the usual caution because they come from company materials, but they align with the broader clinical reality that many OSA patients struggle with PAP persistence and need alternatives. (livanova.gcs-web.com)

What to watch: The next milestones are commercial, not regulatory: final labeling uptake, payer coverage, physician training, and launch execution. Trade reporting suggests LivaNova is targeting a 2027 U.S. launch, so the key question now is whether the company can translate PMA approval into a practical market position against Inspire and into a therapy pathway sleep specialists, surgeons, and payers are willing to use at scale. More broadly, aura6000 is another sign that FDA is seeing a steady flow of implantable neuromodulation products across very different indications, from airway control to cognitive recovery, which could keep investor and clinical attention on the category. (medicaldevice-network.com)